Non-Sponsored Content
CARDIOVASCULAR DISEASE
ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
Medical writer: Kirsty LEE | Last updated: 7 December 2020 | In: Gastrointestinal Cancer, Lung Cancer, Oncology, Immunotherapy, Guidelines, Targeted Therapies
Article Keywords
Bayer, Cyramza, atezolizumab, TKI, Keytruda, ramucirumab, Eli Lilly, α-fetoprotein, MSD, Ipsen, Opdivo, regorafenib, Eisai, Genentech, Stivarga, lenvatinib, Tecentriq, ASCO guidelines, HCC, Lilly, pembrolizumab, Bristol-Meyers Squibb, bevacizumab, Avastin, Merck, cirrhosis, BMS, Cabometyx, Roche, hepatocellular carcinoma, cabozantinib, Lenvima, nivolumab, liver cancer, sorafenib, Nexavar, systemic therapy
Hepatocellular carcinoma (HCC) accounts for 80% of all liver cancers, and 55% of all HCC cases worldwide are reported from China.1Zhu RX et al. Gut Liver. 2016;10(3):332-339. In Hong Kong, liver cancer is the fourth most common cancer and the third most common cause of cancer death.1Zhu RX et al. Gut Liver. 2016;10(3):332-339. Clinical advancements over past decade has led to a number of systemic therapies introduced for the treatment of HCC.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672. The American Society of Clinical Oncology (ASCO) recently released guidelines for the use of systemic therapies in treating advanced HCC.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672.
The ASCO guidelines had the following, notable changes.
The results of the IMbrave 150 phase III randomised controlled trial (RCT) with atezolizumab plus bevacizumab vs sorafenib showed overall survival (OS) superiority over sorafenib.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672. Atezolizumab in combination with bevacizumab is now recommended by ASCO as a first-line option for advanced HCC patients with Child-Pugh class A status, and an ECOG PS of 0-1, following the management of oesophageal varices when present.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672.
In patients with contraindications to atezolizumab or bevacizumab, sorafenib or lenvatinib may be offered as the first-line treatment for patients with advanced HCC, Child-Pugh class A status, and ECOG PS 0-1.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672. However, treatment with these recommended TKIs may be less effective for patients with more advanced cirrhosis.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672.
For second-line treatment options after immunotherapy, tyrosine kinase inhibitors (TKIs) such as sorafenib, lenvatinib, cabozantinib, or regorafenib may be used.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672. However, following first-line therapy with a TKI, e.g. sorafenib or lenvatinib, the recommended second-line includes cabozantinib, ramucirumab (for patients with α-fetoprotein ≥ 400 ng/mL), regorafenib (for patients who tolerated sorafenib well), or atezolizumab + bevacizumab.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672. Immune checkpoint inhibitors such as pembrolizumab or nivolumab may be considered as second-line options in patients with contraindications to – or unable to tolerate – TKIs.2Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672.
YOU MAY ALSO LIKE
Reference
- Zhu RX et al. Gut Liver. 2016;10(3):332-339
- Gordan JD et al. J Clin Oncol. Published online November 16, 2020:JCO.20.02672.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2020 MediPaper Medical Communications Ltd. – ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
YOU MAY ALSO LIKE
© Copyright 2020 MediPaper Medical Communications Ltd. – ASCO Guidelines for the Use of Systemic Therapies in Advanced Hepatocellular Cancer
Leave a Reply
Want to join the discussion?Feel free to contribute!